NGUYEN, HOANG OANH
 Distribuzione geografica
Continente #
NA - Nord America 85
EU - Europa 60
AS - Asia 50
OC - Oceania 1
SA - Sud America 1
Totale 197
Nazione #
US - Stati Uniti d'America 84
IT - Italia 32
SG - Singapore 23
HK - Hong Kong 12
GB - Regno Unito 10
FI - Finlandia 9
ID - Indonesia 6
IE - Irlanda 6
TR - Turchia 5
DE - Germania 3
CN - Cina 2
AU - Australia 1
CA - Canada 1
CL - Cile 1
IN - India 1
LK - Sri Lanka 1
Totale 197
Città #
Singapore 22
Brescia 19
Chandler 16
Hong Kong 12
New York 12
Princeton 10
Helsinki 9
Ashburn 7
Dublin 6
Jakarta 6
Istanbul 5
Cagliari 4
Palazzolo sull'Oglio 4
Fairfield 3
Kilburn 3
London 2
Middlesbrough 2
Shanghai 2
Ann Arbor 1
Cambridge 1
Clifton 1
Colombo 1
Des Moines 1
Falkenstein 1
Hounslow 1
Huntington 1
Melbourne 1
Pavia 1
Pune 1
Rome 1
Romola 1
Santa Clara 1
Seattle 1
Toronto 1
Trieste 1
Wilmington 1
Totale 162
Nome #
ANTI-INFLAMMATORY PROPERTIES OF PDE4 INHIBITION IN SARS-COV-2-ACTIVATED HUMAN DENDRITIC CELLS 43
SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8 41
Inhibition of Class I Histone Deacetylase Activity Blocks the Induction of TNFAIP3 Both Directly and Indirectly via the Suppression of Endogenous TNF-α 32
The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs 27
The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils 25
The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation 24
Modulation of Human Dendritic Cell Functions by Phosphodiesterase-4 Inhibitors: Potential Relevance for the Treatment of Respiratory Diseases 12
Totale 204
Categoria #
all - tutte 2.617
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.617


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202233 0 0 5 1 2 0 0 1 4 5 2 13
2022/202356 6 1 11 2 5 12 0 8 6 0 1 4
2023/202466 4 0 5 6 6 17 3 4 12 0 0 9
2024/202549 4 0 3 29 13 0 0 0 0 0 0 0
Totale 204